Catherine J. Wu

Aug 12, 2024 | cancernetwork.com | Catherine J. Wu

In a conversation with CancerNetwork®, Catherine J. Wu, MD, spoke about the ongoing development of cancer vaccines as a potentially “cross-cutting” therapeutic strategy for treating patients with cancer.

Mar 21, 2024 | cancernetwork.com | Catherine J. Wu

Based on previous studies, cancer vaccines may work well in combination with immunotherapy options such as immune checkpoint blockade for patients with different types of cancer, said Catherine J. Wu, MD.

Mar 19, 2024 | cancernetwork.com | Catherine J. Wu

It will be important to ensure that cancer vaccines can be manufactured and administered more quickly as research expands how patients can have the best possible immune response to this modality, said Catherine J. Wu, MD.

Mar 18, 2024 | cancernetwork.com | Catherine J. Wu

Defining alternative, targetable antigens that may have an impact on treatment is a key area in the research of cancer vaccines, especially for patients with tumors that have a low mutation burden, according to Catherine J. Wu, MD.

Nov 8, 2023 | nature.com | Caleb A Lareau |Yajie Yin |Katie Maurer |Katalin Sandor |Bence Daniel |Jose Sanz Peña | +20 more

AbstractCell therapies have yielded durable clinical benefits for patients with cancer, but the risks associated with the development of therapies from manipulated human cells are understudied. For example, we lack a comprehensive understanding of the mechanisms of toxicities observed in patients receiving T cell therapies, including recent reports of encephalitis caused by reactivation of human herpesvirus 6 (HHV-6)1.